Is there a genetic component to motion sickness?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, There Is a Strong Genetic Component to Motion Sickness

Twin studies demonstrate that genetic factors account for approximately 57% of motion sickness susceptibility, with heritability reaching as high as 70% during childhood 1. This genetic influence has been confirmed through multiple lines of evidence including genome-wide association studies, family pedigree analyses, and identification of specific genetic variants.

Evidence for Genetic Contribution

The genetic basis of motion sickness is well-established through several complementary research approaches:

Twin Studies Provide the Strongest Evidence

A classical twin study of 3,652 adult female twins found heritability of 57% (95% CI: 51-63%) for motion sickness susceptibility 1. The genetic contribution was highest in childhood at 70% and declined through puberty into early adulthood 1. This twin study design effectively separates genetic from environmental influences, providing robust evidence for hereditary factors 2, 3.

Specific Genetic Variants Have Been Identified

The first genome-wide association study (GWAS) on motion sickness identified 35 single-nucleotide polymorphisms (SNPs) significantly associated with motion sickness susceptibility 4. These genetic variants cluster near genes involved in:

  • Balance and vestibular function (e.g., PVRL3, TSHZ1, MUTED)
  • Eye, ear, and cranial development (e.g., HOXB3, HOXD3)
  • Nervous system function
  • Glucose homeostasis and hypoxia response

Notably, several SNPs display sex-specific effects with up to three times stronger effects in women 4, which aligns with clinical observations of higher female susceptibility.

Additional Genetic Evidence

  • Genetic polymorphisms of the alpha-2-adrenergic receptor increase motion sickness susceptibility 3
  • Family pedigree studies reveal heritable patterns of motion sickness susceptibility 3
  • Ethnic variations exist, with evidence suggesting Asians may have heightened susceptibility 3
  • Epigenetic modulation may contribute to both susceptibility and habituation 5

Clinical Implications

Individual Susceptibility Varies Widely

Approximately 40% of adults report at least moderate susceptibility to motion sickness 1. The genetic component explains why some individuals are highly susceptible while others rarely experience symptoms under similar conditions 2.

Risk Factors Beyond Genetics

While genetics plays the dominant role, other factors modulate susceptibility:

  • Age: Younger persons are more susceptible 2
  • Sex: Women are more susceptible than men 2, 4
  • Prior exposure and habituation: Can modify genetic predisposition 5

Evolutionary Perspective

The high heritability suggests motion sickness evolved as a negative reinforcement system to prevent behaviors involving postural instability or sensory conflict 3. This evolutionary model is supported by the extensive genetic evidence demonstrating heritable predisposition.

Practical Considerations

The genetic basis of motion sickness means that:

  • Family history is relevant when assessing individual risk
  • Susceptibility is largely predetermined but can be modified through habituation
  • Pharmacological interventions (scopolamine, H1-antihistamines like dimenhydrinate and cinnarizine) remain important for genetically susceptible individuals 2
  • Behavioral modifications and repeated exposure can help overcome genetic predisposition through habituation 5, 6

The identification of specific genetic variants opens potential future avenues for personalized risk assessment and targeted therapies, though current management remains focused on pharmacological and behavioral interventions regardless of genetic background.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.